This is a randomized controlled trial of injectable intramuscular naltrexone (XR-NTX) versus
intramuscular placebo among HIV-infected prisoners meeting Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence or problem
drinking, who are transitioning to the community and seeking treatment to prevent relapse to
alcohol use. We hypothesize that extended release naltrexone (XR-NTX) will result in improved
HIV outcomes (lower log10 HIV-1RNA levels and higher CD4 count) as well as improved alcohol
treatment outcomes, and reduced drug/sex HIV related risk behaviors and decreased rates of
reincarceration.
Phase:
N/A
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)